InDex Pharmaceuticals Holding AB (publ) interim report January – March 2022
Full focus on the phase III study CONCLUDE with cobitolimod“With a new management team in place, I look forward to a continued exciting and important year with full focus on the phase III study CONCLUDE with cobitolimod”, says Johan Giléus, acting CEO of InDex Pharmaceuticals. Period January – March 2022 · Net sales amounted to SEK 0.0 (0.0) million · Operating loss amounted to SEK –18.9 (–9.3) million · Result after tax amounted to SEK –18.9 (–9.3) million, corresponding to SEK –0.04 per share (–0.02) before and after dilution · Cash flow from operating activities amounted